Filing Flows › Impact Biomedical (IBO) › Q2 2026
Impact Biomedical (IBO) Q2 2026 earnings results (second quarter 2026)
10-Q filed Aug 7, 2026
Impact Biomedical (IBO) reported revenue of $3K for the second quarter 2026 (Q2 2026), -57% from a year earlier and -57% from the quarter before.
Impact Biomedical, Q2 2026: revenue $3K (-57% year over year), net loss $700K, operating cash flow $470K. The chart follows the revenue to costs, profit and cash.
| Q2 2026 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $3K | -57% | -57% |
| Operating profit | −$702K | — | — |
| Net earnings | −$700K | — | — |
| Operating cash flow | $470K | — | — |
What changed
Revenue was $3K in Q2 2026, down 57% year over year and down 57% from the previous quarter.
Operating costs exceeded revenue by $702K, an operating margin of -23400.0%. Total costs fell 39% while revenue fell 57%. The quarter ended with a net loss of $700K, narrower than the previous quarter's $2.3M loss. Minority interests bore $1K of it: to shareholders the quarter was a loss of $699K.
Operating cash flow was $470K. Non-cash charges added back $284K of depreciation and amortization. Working capital and other items added $886K.
Questions
What was Impact Biomedical's revenue in the second quarter 2026?
Impact Biomedical (IBO) reported revenue of $3K for the second quarter 2026 (Q2 2026), -57% from a year earlier and -57% from the quarter before.
Source: Impact Biomedical 10-Q on SEC EDGAR.